Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

4,520JPY
13 Nov 2018
Change (% chg)

¥-39 (-0.86%)
Prev Close
¥4,559
Open
¥4,513
Day's High
¥4,546
Day's Low
¥4,478
Volume
7,039,900
Avg. Vol
4,693,324
52-wk High
¥6,693
52-wk Low
¥4,203

Latest Key Developments (Source: Significant Developments)

Takeda Comments On Ongoing Review By European Commission Of Proposed Deal Of Shire PLC
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA COMMENTS ON ONGOING PHASE 1 REVIEW BY THE EUROPEAN COMMISSION OF THE PROPOSED ACQUISITION OF SHIRE PLC.TAKEDA - DOES NOT ANTICIPATE THAT DISCUSSIONS WITH EC WILL RESULT IN A DELAY TO ITS PREVIOUSLY ANNOUNCED TIMETABLE FOR COMPLETION OF TRANSACTION.TAKEDA -CONFIRMS IN DISCUSSIONS WITH EC IN RELATION TO FUTURE OVERLAP IN AREA OF INFLAMMATORY BOWEL DISEASE BETWEEN CO'S ENTYVIO & SHIRE'S SHP647.TAKEDA PHARMACEUTICAL CO LTD - CONFIRMS THERE ARE NO DISCUSSIONS WITH EC REGARDING ANY OTHER MARKETED PRODUCTS OR ASSETS IN PIPELINE.  Full Article

Takeda Gets Clearance From Japan Fair Trade Commission For Shire Deal
Thursday, 18 Oct 2018 

Oct 18 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::RECEIVED UNCONDITIONAL CLEARANCE FROM JAPAN FAIR TRADE COMMISSION FOR PROPOSED ACQUISITION OF SHIRE.  Full Article

Medrx signs technology license agreement with Takeda
Monday, 27 Aug 2018 

Aug 27(Reuters) - Medrx Co Ltd <4586.T>:Says it signed a technology license agreement with Takeda Pharmaceutical Co Ltd <<<4502.T>>>, to support the development of selected Takeda pipeline compounds in a focused therapeutic area with its proprietary technology for transdermal drug delivery, on Aug. 24.  Full Article

Takeda Says Entered Into Term Loan Credit Agreement For Up To $7.5 Billion For Shire Acquisition
Friday, 8 Jun 2018 

June 8 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA SAYS ENTERED INTO TERM LOAN CREDIT AGREEMENT FOR UP TO $7.5 BILLION FOR SHIRE ACQUISITION.  Full Article

Myovant Sciences' Unit Entered Agreement With Takeda Regarding Relugolix
Tuesday, 5 Jun 2018 

June 5 (Reuters) - Myovant Sciences Ltd: :MYOVANT SCIENCES - EFFECTIVE MAY 30, CO'S UNIT ENTERED COMMERCIAL MANUFACTURING & SUPPLY AGREEMENT WITH TAKEDA PHARMACEUTICAL REGARDING RELUGOLIX.MYOVANT - PURSUANT TO AGREEMENT, TAKEDA AGREED TO SUPPLY TO MSG & MSG AGREED TO GET FROM TAKEDA CERTAIN QUANTITIES OF RELUGOLIX DRUG SUBSTANCE.MYOVANT- RELUGOLIX DRUG SUBSTANCE SUPPLY & OBTAINMENT WITH TAKEDA AS PER AGREED-UPON QUALITY SPECIFICATIONS, IN ORDER TO COMMERCIALIZE RELUGOLIX.  Full Article

Wave Life Sciences Reports Qtrly Loss Per Share $1.26
Wednesday, 9 May 2018 

May 9 (Reuters) - WAVE Life Sciences Ltd ::WAVE LIFE SCIENCES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.WAVE LIFE SCIENCES LTD QTRLY LOSS PER SHARE $1.26.WAVE LIFE SCIENCES LTD - ENDED Q1 OF 2018 WITH $110.5 MILLION IN CASH AND CASH EQUIVALENTS.WAVE LIFE SCIENCES - EXPECTS CASH, CASH EQUIVALENTS, $170.0 MILLION CASH FROM TAKEDA IN APRIL, ENABLE FUNDING OPERATING, CAPEX REQUIREMENTS TO 2020 END.  Full Article

Takeda Pharmaceutical says execution of bridge loan agreement for Shire plc acquisition
Tuesday, 8 May 2018 

May 8(Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>:Says it signed 364-Day Bridge Credit Agreement worth up to $30.85 billion for Shire plc acquisition on May 8 .  Full Article

Takeda Responds to Media Reports About CEO's Comments On Possible Offer For Shire
Friday, 6 Apr 2018 

April 6 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::STATEMENT REGARDING PRESS REPORTS.‍NOTES MEDIA REPORTS ABOUT COMMENTS ATTRIBUTED TO TAKEDA'S CEO CHRISTOPHE WEBER REGARDING COMPANY'S POSSIBLE OFFER FOR SHIRE PLC​.‍"CONFIRMS THAT WEBER'S COMMENTS WERE, HOWEVER, ALIGNED WITH STATEMENTS IN OUR PREVIOUS PRESS RELEASES"​.‍ PRIOR STATEMENTS "CLEARLY DEFINED STRATEGIC AND FINANCIAL OBJECTIVES CORE TO ITS DISCIPLINED APPROACH TO ACQUISITIONS".‍"ANY POTENTIAL OFFER FOR SHIRE, IF MADE, WOULD HAVE TO ALIGN WITH THE STRICT INVESTMENT CRITERIA"​.  Full Article

Rhythm Pharma Announces Licensing Agreement With Takeda
Monday, 2 Apr 2018 

April 2 (Reuters) - Rhythm Pharmaceuticals Inc ::RHYTHM PHARMACEUTICALS ANNOUNCES LICENSING AGREEMENT WITH TAKEDA FOR THE DEVELOPMENT AND COMMERCIALIZATION OF PRECLINICAL TREATMENT FOR PRADER-WILLI SYNDROME.RHYTHM PHARMACEUTICALS INC - ‍RHYTHM EXPECTS TO FILE INVESTIGATIONAL NEW DRUG APPLICATION IN Q1 OF 2020​.RHYTHM PHARMACEUTICALS INC - ‍ ACQUIRED EXCLUSIVE, WORLDWIDE RIGHTS FROM TAKEDA TO DEVELOP AND COMMERCIALIZE T-3525770 (NOW RM-853)​.RHYTHM PHARMACEUTICALS INC - ‍UNDER TERMS, CO WILL ASSUME SOLE RESPONSIBILITY FOR GLOBAL PRODUCT DEVELOPMENT AND COMMERCIALIZATION OF RM-853​.RHYTHM PHARMACEUTICALS-‍ TAKEDA TO GET UPFRONT PAYMENT OF $5 MLN IN CO'S STOCK, BACK-END DEVELOPMENT MILESTONES, SINGLE-DIGIT ROYALTIES ON RM-853 SALES​.RHYTHM PHARMACEUTICALS INC - ‍WILL EXPLORE OPPORTUNITIES TO EVALUATE SETMELANOTIDE AND RM-853 IN COMBINATION, AS THERE MAY BE COMPLEMENTARY EFFECTS​​.  Full Article

Shire Confirms It Has Not Received Approach From Takeda
Wednesday, 28 Mar 2018 

March 28 (Reuters) - Shire Plc ::REG-SHIRE PLC : STATEMENT RE POSSIBLE OFFER.‍NOTES ANNOUNCEMENT BY TAKEDA PHARMACEUTICAL COMPANY LIMITED​.SHIRE CONFIRMS THAT IT HAS NOT RECEIVED AN APPROACH FROM TAKEDA..  Full Article

UK Stocks-Factors to watch on Nov 13

Nov 13 Britain's FTSE 100 index is seen opening 15 points higher at 7,068 on Tuesday, according to financial bookmakers. * SHIRE, TAKEDA: Banks, law firms and other advisers stand to earn up to $963 million in fees from Takeda Pharmaceutical's $62 billion takeover of drugmaker Shire, according to documents for the deal published on Monday. * IQE: British chipmaker IQE Plc warned on Monday that its current-year financial results would be lower, after fellow Apple sup